Trials / Completed
CompletedNCT04302103
A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
A Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Systemic Myasthenia Gravis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RC18 160mg | subcutaneous injection |
| BIOLOGICAL | RC18 240 mg | subcutaneous injection |
Timeline
- Start date
- 2020-07-07
- Primary completion
- 2022-01-14
- Completion
- 2022-02-11
- First posted
- 2020-03-10
- Last updated
- 2023-10-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04302103. Inclusion in this directory is not an endorsement.